• Thurs news: Novartis not joining weight loss race. Pharma marketing and climate change. Roche flu treatment trial. Cercle’s fund raise for women’s health. ICER looks at GSK COPD drugs. See more on our front page

Viatris' launch plans scuttled as FDA rebuffs long-acting MS drug from partner Mapi

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Mar 11, 2024 at 11:42: AM
via Viatris likely just lost one of its top product debuts for 2024, thanks to an FDA rejection of its partner Mapi Pharma’s application for a new version of Teva’s multiple sclerosis (MS) drug Copaxone.

article source
 

<



Similar threads

cafead
Novartis, Viatris face new lawsuit over &#039;HeLa&#039; cell misuse claims
Replies
0
Views
30
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
At Viatris&#039; request, US agency will review another Novo Nordisk patent on semaglutide
Replies
0
Views
137
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
J&amp;J beats back Viatris&#039; generic challenge to schizophrenia med Invega Trinza
Replies
0
Views
100
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
FDA rejects Biocon and Viatris&#039; Avastin biosimilar after inspection question marks
Replies
0
Views
294
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
J&amp;J&#039;s Momenta calls infringement against Viatris&#039; Copaxone generic, but why now?
Replies
0
Views
118
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote